A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks

Phase 1 Targeted Combination Trial Of PF-00299804 And CP-751,871 In Patients With Advanced Solid Tumors

This study will explore the combination of the oral drug PF-00299804 and intravenous CP-751,871 in patients with advanced solid tumor. Each of these drugs have been given separately to patients in prior studies, and this study is to establish the safety and efficacy of the combination.

Inclusion Criteria:

• Histologically documented advanced cancer, Eastern Cooperative Oncology Group (ECOG) 0-1;
• Platelets > 100,000, ANC > 1500;
• Ccr > 60 or serum creat. <1.5
• Non-small cell cancer cohort:
• Eastern Cooperative Oncology Group (ECOG) 0-2, prior platin, < 4 prior chemotherapy regimen
• HgA1C <5.7%

Exclusion Criteria:

• Active Central Nervous System (CNS) metastases;
• prior IGF1-R targeted therapy
• Any history of unstable angina, myocardial infarction or symptomatic congestive heart failure.